Melinda Mariotti

Dr. Melinda Mariotti

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
Maura Di VitoMaura Di Vito
Maura Di Vito
SGS. Garzoli
S. Garzoli
RRR. Rosato
R. Rosato
MMMelinda Mariotti
Melinda Mariotti
JGJ. Gervasoni
J. Gervasoni
FBF. Bugli
F. Bugli
This study highlights how small doses of CZ-EO are able to inhibit the secretion of fluconazole and promote its accumulation in the fungal cell. In this manner, the drug is able to exert its pharmacological effects bypassing the resistance of the yeast. If further studies will confirm this synergy, it will be possible to develop new therapeutic formulations active in the fight against C. auris resistances.

15 April 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
MMMelinda Mariotti
Melinda Mariotti
GLGiulia Lombardini
Giulia Lombardini
SRSilvia Rizzo
Silvia Rizzo
DSDonatella Scarafile
Donatella Scarafile
MMMonica Modesto
Monica Modesto
Paola MattarelliPaola Mattarelli
Paola Mattarelli
The extensive use of antibiotics has contributed to the current antibiotic resistance crisis. Livestock infections of Salmonella spp, Clostridium spp. and E. coli antimicrobial-resistant bacteria represent a public threat to human and animal health. To reduce the incidence of these zoonoses, essential oils (EOs) could be effective antibiotic alternatives. This study aims at identifying EOs safe for use, effective both in complementary therapy and in the environmental sanitization of intensive farming. Natural products were chemo-characterized by gas chromatography. Three S. Typhimurium, three C. perfringens and four E. coli strains isolated from poultry and swine farms were used to assess the antimicrobial properties of nine EOs and a modified GR-OLI (mGR-OLI). The toxicity of the most effective ones (Cinnamomum zeylanicum, Cz; Origanum vulgare, Ov) was also evaluated on porcine spermatozoa and Galleria mellonella larvae. Cz, Ov and mGR-OLI showed the strongest antimicrobial activity; their volatile components were also able to significantly inhibit the growth of tested strains. In vitro, Ov toxicity was slightly lower than Cz, while it showed no toxicity on G. mellonella larvae. In conclusion, the study confirms the importance of evaluating natural products to consolidate the idea of safe EO applications in reducing and preventing intensive livestock infections.

Verified
Journal Article
Open access
PDF file
FBFrancesca Bugli
Francesca Bugli
FMFederica Massaro
Federica Massaro
Francesco BuonocoreFrancesco Buonocore
Francesco Buonocore
PSPaolo Roberto Saraceni
Paolo Roberto Saraceni
SBStefano Borocci
Stefano Borocci
FPFernando Porcelli
Fernando Porcelli
The increasing resistance of fungi to antibiotics is a severe challenge in public health, and newly effective drugs are required. Promising potential medications are lipopeptides, linear antimicrobial peptides (AMPs) conjugated to a lipid tail, usually at the N-terminus. In this paper, we investigated the in vitro and in vivo antifungal activity of three short myristoylated and non-myristoylated peptides derived from a mutant of the AMP Chionodracine. We determined their interaction with anionic and zwitterionic membrane-mimicking vesicles and their structure during this interaction. We then investigated their cytotoxic and hemolytic activity against mammalian cells. Lipidated peptides showed a broad spectrum of activity against a relevant panel of pathogen fungi belonging to Candida spp., including the multidrug-resistant C. auris. The antifungal activity was also observed vs. biofilms of C. albicans, C. tropicalis, and C. auris. Finally, a pilot efficacy study was conducted on the in vivo model consisting of Galleria mellonella larvae. Treatment with the most-promising myristoylated peptide was effective in counteracting the infection from C. auris and C. albicans and the death of the larvae. Therefore, this myristoylated peptide is a potential candidate to develop antifungal agents against human fungal pathogens.

19 January 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
Maura Di VitoMaura Di Vito
Maura Di Vito
LVLara Vergari
Lara Vergari
MMMelinda Mariotti
Melinda Mariotti
MPMaria Rita Proto
Maria Rita Proto
Lorenzo BarbantiLorenzo Barbanti
Lorenzo Barbanti
DLDaphne De Luca
Daphne De Luca
A modern painting is characterized by multi-material bases extremely exposed to biodeteriogenic attacks. The aim of this work was to test the antifungal effectiveness of a natural, eco-friendly, and safe emulsion based on Citrus aurantium L. var. amara hydrolate and Cinnamomum zeylanicum Blume (from bark) essential oil, named “Zeylantium green emulsion” (Zege), on modern paintings. Colored unaged and aged canvas samples, performed with modern techniques (acrylic, vinylic and alkyd), were used to test in vitro both the antifungal effectiveness of Zege and its impact on the chemical–physical characteristics. Microbiological tests were performed according to the EUCAST international guidelines. pH measurements and colorimetric analysis were performed on unaged and aged canvases before and after Zege spray treatment. Finally, in situ tests were performed using the spray emulsion on canvas samples obtained from Ilaria Margutti’s modern artwork, which had been colonized by molds. Microbiological tests on canvas prototypes showed a time- and dose-dependent effectiveness of the Zege spray. None of the techniques underwent relevant changes in pH. Only the acrylic colors were unaffected in the colorimetric analysis, among all colored unaged or aged canvases. Tests made with modern artwork samples confirmed the in situ antifungal effectiveness. The Zege spray showed encouraging results in regard to the use of this formulation in the restoration of modern paintings.

19 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Damiano SquitieriDamiano Squitieri
Damiano Squitieri
SRSilvia Rizzo
Silvia Rizzo
RTRiccardo Torelli
Riccardo Torelli
MMMelinda Mariotti
Melinda Mariotti
Maurizio SanguinettiMaurizio Sanguinetti
Maurizio Sanguinetti
FBFrancesca Bugli
Francesca Bugli
Candida biofilms play a critical role in clinical settings, contributing to persistent and device-associated infections and conferring resistance to antifungal agents, particularly in immunocompromised or hospitalized patients. Biofilm formation varies among Candida species, including C. albicans and non-albicans species, such as C. glabrata, C. tropicalis, C. parapsilosis, and C. auris, due to species-specific transcriptional networks that regulate modes of biofilm development, extracellular matrix composition, and metabolic reprogramming. These differences influence biofilm responses to treatment and the severity of infections, which can be further complicated in polymicrobial biofilms that modulate colonization and virulence. Understanding the mechanisms driving biofilm formation and interspecies interactions is essential for developing effective therapies and requires appropriate experimental models. Available models range from simplified in vitro systems to more complex ex vivo and in vivo approaches. Static in vitro models remain widely used due to their simplicity and reproducibility, but they poorly mimic physiological conditions and require careful standardization. Ex vivo tissue models offer a balance between practicality and biological relevance, enabling the study of biofilm physiology, host–microbe interactions and immune responses. In vivo models, primarily in mice, remain the gold standard for testing antifungal therapies, while alternative systems such as Galleria mellonella larvae provide simpler, cost-effective approaches. Advanced in vitro platforms, including organ-on-chip systems, bridge the gap between simplified tests and physiological relevance by simulating fluid dynamics, tissue architecture, and immune complexity. This review aims to examine Candida biofilms across species, highlighting differences in structural diversity and clinical implications, and to provide a guide to the most widely used experimental models supporting studies on Candida biofilm biology for the development of new therapeutic targets or drug testing.

10 February 2022 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
LBLorenzo J. I. Balestri
Lorenzo J. I. Balestri
Ilaria D'AgostinoIlaria D'Agostino
Ilaria D'Agostino
EREnrico Rango
Enrico Rango
CVChiara Vagaggini
Chiara Vagaggini
RMRosalba Marchitiello
Rosalba Marchitiello
Elena DreassiElena Dreassi
Elena Dreassi